Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116949573 | 11694957 | 3 | F | 20160623 | 20151103 | 20160701 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-073847 | BRISTOL MYERS SQUIBB | 0.00 | M | Y | 0.00000 | 20160701 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116949573 | 11694957 | 1 | PS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 20 MG, QD | Y | 21436 | 20 | MG | TABLET | QD | |||||
| 116949573 | 11694957 | 2 | SS | ABILIFY MAINTENA | ARIPIPRAZOLE | 1 | Intramuscular | 400 MG, QMO | Y | 0 | 400 | MG | /month |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116949573 | 11694957 | 1 | Schizophrenia |
| 116949573 | 11694957 | 2 | Schizophrenia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116949573 | 11694957 | HO |
| 116949573 | 11694957 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116949573 | 11694957 | Delirium | |
| 116949573 | 11694957 | Drug effect decreased | |
| 116949573 | 11694957 | Psychotic disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 116949573 | 11694957 | 1 | 201502 | 0 |